4B). To identify genome-wide hepatic FXR-binding sites in healthy and obese mice, mice were fed normal or high-fat chow for 20 weeks and then treated for a short time (1 hour) with a synthetic FXR agonist, GW4064, to activate FXR signaling. ChIP assays from liver chromatin were performed with FXR antibody or control IgG. The quality of the ChIP assay was confirmed by the increased binding of FXR to known FXR targets, Shp and organic solute transporter beta, and increased levels of Shp mRNA also confirmed Dabrafenib mouse the effectiveness

of the GW4064 treatment (Supporting Fig. 5). The ChIP-seq analysis generated 2.98 and 3.97 million reads for GW4064-treated healthy and obese mice, respectively (Supporting Fig. 6). FXR-binding peak analysis, with stringent FDR cutoffs of <0.001 and the elimination of peaks observed also with control IgG, identified a total of 15,263 and 5,272 FXR-binding sites in GW4064-treated healthy and obese mice, respectively (Fig. 1A, top). Of these sites, 7,440 or 2,344 were uniquely detected in healthy or high-fat dietary obese mice (Fig. 1A, bottom). The number of overlapping sites in the healthy mice was greater than

that in the obese mice, because some of the FXR-binding sites in the obese group overlapped with two or more binding sites in the healthy group. To validate the ChIP-seq data, we randomly selected FXR-binding sites. Neither the size nor position of FXR-binding peaks 上海皓元医药股份有限公司 was considered to select binding sites for validation beta-catenin inhibitor and follow-up studies. ChIP assays revealed that binding to 24 of 27 sites in healthy mice and 20 of 21 in obese mice was enriched by at least 1.8-fold relative to vehicle-treated mice (Supporting Figs. 7 and 8), confirming binding to approximately 90% of these sites and validating the accuracy of the ChIP-seq analysis. The central question of this study was to determine whether FXR regulation might be altered

in obesity, which could underlie abnormal liver function and metabolism. Therefore, we focused on the differences in FXR binding between GW4064-treated healthy and obese mice. Notably, 7,440 of the total 15,632 FXR-binding sites in healthy mice were unique in these mice, whereas 2,344 of the total 5,272 sites in obese mice were unique (Fig. 1A). Potential FXR target genes were identified based on the criteria that an FXR-binding site was within 10 kb of the gene. FXR-binding sites corresponded to 2,583 or 1,566 potential target genes unique in healthy or obese mice (Fig. 1A). These results indicate that nearly half of the total FXR-binding sites are unique in healthy or obese mice, suggesting that transcriptional regulation patterns by FXR are likely altered in obesity. Binding sites of FXR were predominantly distributed in intron (38%) and intergenic (40%) regions in both groups of mice (Fig. 1B).